amifostine anhydrous has been researched along with pilocarpine in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (8.33) | 18.2507 |
| 2000's | 8 (66.67) | 29.6817 |
| 2010's | 2 (16.67) | 24.3611 |
| 2020's | 1 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Miller, EG; Taylor, SE | 1 |
| Aframian, DJ; Nahlieli, O; Palmon, A | 1 |
| Hakim, SG; Kosmehl, H; Lauer, I; Nadrowitz, R; Sieg, P; Wedel, T | 1 |
| Johnstone, PA; Kahn, ST | 1 |
| de Castro, G; Federico, MH | 1 |
| Beutel, J; Geerling, G; Hakim, SG; Kosmehl, H; Rades, D; Schroder, C; Sieg, P; von Hof, K; Wedel, T | 1 |
| Hodgson, TA; Schiødt, M; Shiboski, CH; Ship, JA | 1 |
| Glenny, AM; Hua, F; Riley, P; Worthington, HV | 1 |
| Anothaisintawee, T; Auttara-Atthakorn, A; Reutrakul, S; Sriphrapradang, C; Sungmala, J | 1 |
7 review(s) available for amifostine anhydrous and pilocarpine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Preemptive pharmacologic intervention in radiation-induced salivary dysfunction.
Topics: Adrenergic beta-Agonists; Amifostine; Animals; Head and Neck Neoplasms; Humans; Iatrogenic Disease; In Vitro Techniques; Isoproterenol; Muscarinic Agonists; Pilocarpine; Radiation Injuries; Radiation Tolerance; Radiation-Protective Agents; Salivary Glands; Transplantation Conditioning; Whole-Body Irradiation; Xerostomia | 1999 |
Management of xerostomia related to radiotherapy for head and neck cancer.
Topics: Acupuncture Therapy; Amifostine; Clinical Trials as Topic; Head and Neck Neoplasms; Humans; Muscarinic Agonists; Palliative Care; Pilocarpine; Quinuclidines; Radiation-Protective Agents; Radiotherapy; Submandibular Gland; Thiophenes; Xerostomia | 2005 |
Evaluation, prevention and management of radiotherapy-induced xerostomia in head and neck cancer patients.
Topics: Amifostine; Carcinoma, Squamous Cell; Clinical Trials as Topic; Cytoplasmic Granules; Free Radical Scavengers; Head and Neck Neoplasms; Humans; Lipid Peroxidation; Parasympathomimetics; Pilocarpine; Radiation Injuries; Radiation-Protective Agents; Radiotherapy; Radiotherapy, Intensity-Modulated; Salivary Glands; Xerostomia | 2006 |
Management of salivary hypofunction during and after radiotherapy.
Topics: Amifostine; Dental Caries; Humans; Muscarinic Agonists; Pilocarpine; Radiation Injuries; Radiation-Protective Agents; Radiotherapy; Saliva, Artificial; Salivary Glands; Xerostomia | 2007 |
Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy.
Topics: Amifostine; Drugs, Chinese Herbal; Female; Fibroblast Growth Factor 7; Humans; Male; Pilocarpine; Quality of Life; Radiation-Protective Agents; Radiotherapy; Randomized Controlled Trials as Topic; Saliva, Artificial; Salivary Gland Diseases; Salivary Glands; Salivation; Xerostomia | 2017 |
Prevention of salivary gland dysfunction in patients treated with radioiodine for differentiated thyroid cancer: A systematic review of randomized controlled trials.
Topics: Adenocarcinoma; Amifostine; Bethanechol; Humans; Iodine Radioisotopes; Pilocarpine; Randomized Controlled Trials as Topic; Salivary Glands; Selenium; Thyroid Neoplasms; Vitamin E | 2022 |
5 other study(ies) available for amifostine anhydrous and pilocarpine
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
[Future therapy strategies for salivary gland impairment].
Topics: Amifostine; Cranial Irradiation; Head and Neck Neoplasms; Humans; Muscarinic Agonists; Pilocarpine; Quinuclidines; Radiation Injuries; Radiation-Protective Agents; Regeneration; Saliva; Salivary Glands; Thiophenes | 2004 |
A comparative study on the protection profile of lidocaine, amifostine, and pilocarpin on the parotid gland during radiotherapy.
Topics: Actins; Amifostine; Animals; Drug Synergism; Female; Lidocaine; Microscopy, Electron, Transmission; Parotid Gland; Pilocarpine; Rabbits; Radiation-Protective Agents; Tenascin | 2005 |
New approaches to preventing xerostomia.
Topics: Amifostine; Cytoprotection; Humans; Muscarinic Agonists; Neoplasms; Pilocarpine; Quinuclidines; Radiation Injuries; Radiation-Protective Agents; Radiotherapy Dosage; Radiotherapy, Intensity-Modulated; Salivary Glands; Thiophenes; Xerostomia | 2006 |
Pharmacological prevention of radiation-induced dry eye-an experimental study in a rabbit model.
Topics: Actins; Amifostine; Animals; Dry Eye Syndromes; Female; Immunoenzyme Techniques; Lacrimal Apparatus; Lidocaine; Pilocarpine; Rabbits; Radiation Injuries, Experimental; Radiation-Protective Agents; Radionuclide Imaging; Tears; Tenascin; Up-Regulation; X-Rays | 2007 |